

Lakshmi N Yatham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5939193/publications.pdf>

Version: 2024-02-01

149
papers

8,434
citations

66234

42
h-index

49773

87
g-index

154
all docs

154
docs citations

154
times ranked

6866
citing authors

#	ARTICLE	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	0.9	5
2	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 56-82.	1.9	67
3	Longitudinal Structural Brain Changes in Bipolar Disorder: A Multicenter Neuroimaging Study of 1232 Individuals by the ENIGMA Bipolar Disorder Working Group. Biological Psychiatry, 2022, 91, 582-592.	0.7	29
4	Adrift in time: the subjective experience of circadian challenge during COVID-19 amongst people with mood disorders. Chronobiology International, 2022, 39, 57-67.	0.9	5
5	Clinical and demographic factors associated with delayed diagnosis of bipolar disorder: Data from Health Outcomes and Patient Evaluations in Bipolar Disorder (HOPE-BD) study. Journal of Affective Disorders, 2022, 296, 506-513.	2.0	16
6	Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. Journal of Affective Disorders, 2022, 297, 396-400.	2.0	1
7	Use of a point-of-care web-based application to enhance adherence to the CANMAT and ISBD 2018 guidelines for the management of bipolar disorder. Bipolar Disorders, 2022, 24, 392-399.	1.1	3
8	What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines. Journal of Affective Disorders, 2022, 298, 565-576.	2.0	8
9	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	4.1	68
10	Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021: A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disorders, 2022, 24, 354-374.	1.1	23
11	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disorders, 2022, 24, 709-719.	1.1	16
12	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. Bipolar Disorders, 2022, 24, 499-508.	1.1	15
13	Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Canadian Journal of Psychiatry, 2022, 67, 745-754.	0.9	8
14	Social Rhythm Disruption is Associated with Greater Depressive Symptoms in People with Mood Disorders: Findings from a Multinational Online Survey During COVID-19. Canadian Journal of Psychiatry, 2022, 67, 832-841.	0.9	6
15	Cannabidiol in the Treatment of Mood Disorders. Current Treatment Options in Psychiatry, 2022, 9, 140-150.	0.7	1
16	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	1.3	32
17	Preservation of Gray Matter Volume in Early Stage of Bipolar Disorder: A Case for Early Intervention: PrÃ©servation du volume de matiÃ©re grise au stade prÃ©coce du trouble bipolaire: un cas pour intervention prÃ©coce. Canadian Journal of Psychiatry, 2021, 66, 139-146.	0.9	8
18	Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. Canadian Journal of Psychiatry, 2021, 66, 289-297.	0.9	3

#	ARTICLE	IF	CITATIONS
19	Our Digital Moment: Innovations and Opportunities in Digital Mental Health Care. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 5-8.	0.9	43
20	Cognitive subgroups in first episode bipolar I disorder: Relation to clinical and brain volumetric variables. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 151-161.	2.2	18
21	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Ketamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 113-125.	0.9	54
22	The Quality of Life in Bipolar Disorder (QoLBD) questionnaire a decade on – A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder. <i>Journal of Affective Disorders</i> , 2021, 278, 33-45.	2.0	5
23	Early intervention for people at high risk of developing bipolar disorder: a systematic review of clinical trials. <i>Lancet Psychiatry</i> , 2021, 8, 64-75.	3.7	24
24	Grey matter abnormalities in first episode mania: A systematic review and meta-analysis of voxel-based morphometry studies. <i>Bipolar Disorders</i> , 2021, 23, 228-240.	1.1	18
25	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 48.	2.4	9
26	Metacognitive knowledge and experience across multiple cognitive domains in euthymic bipolar disorder. <i>European Psychiatry</i> , 2021, 64, e36.	0.1	4
27	Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 79-90.	1.0	27
28	Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	1
29	Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression. <i>JAMA Network Open</i> , 2021, 4, e210963.	2.8	32
30	Investigating the effect of COVID-19 dissemination on symptoms of anxiety and depression among university students. <i>BJPsych Open</i> , 2021, 7, e69.	0.3	22
31	What impact does bipolar disorder staging have on the use of pharmacotherapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1513-1516.	0.9	2
32	Intermittent Theta-Burst Stimulation Transcranial Magnetic Stimulation Increases GABA in the Medial Prefrontal Cortex: A Preliminary Sham-Controlled Magnetic Resonance Spectroscopy Study in Acute Bipolar Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 665402.	1.3	10
33	New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials. <i>Current Psychiatry Reports</i> , 2021, 23, 39.	2.1	7
34	Expanding the target audience for management guidelines: Co-development of the patient and family guide to the CANMAT and ISBD bipolar disorder guidelines. <i>Bipolar Disorders</i> , 2021, 23, 528-530.	1.1	1
35	Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 288, 191-198.	2.0	7
36	Response to commentary on – Grey matter abnormalities in first episode mania: A systematic review and meta-analysis of voxel-based morphometry studies –. <i>Bipolar Disorders</i> , 2021, 23, 411-413.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. <i>Bipolar Disorders</i> , 2021, 23, 659-678.	1.1	27
38	Why do medications with little or no efficacy continue to be prescribed in the management of patients with bipolar disorder?. <i>Bipolar Disorders</i> , 2021, 23, 541-543.	1.1	2
39	Longitudinal grey matter changes following first episode mania in bipolar I disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2021, 291, 198-208.	2.0	11
40	The Efficacy of Measurement-Based Care for Depressive Disorders. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	21
41	Dopamine release during psychological stress in euthymic bipolar I disorder: a Positron Emission Tomography study with [¹¹ C]raclopride. <i>Journal of Affective Disorders</i> , 2021, 295, 724-732.	2.0	0
42	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. <i>Journal of Affective Disorders</i> , 2021, 295, 740-751.	2.0	33
43	Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. <i>International Clinical Psychopharmacology</i> , 2021, 36, 76-83.	0.9	10
44	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. <i>Bipolar Disorders</i> , 2021, 23, 767-788.	1.1	32
45	Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. <i>Frontiers in Psychiatry</i> , 2021, 12, 769897.	1.3	0
46	Translational chasm and dialogues in clinical neuroscience. <i>Dialogues in Clinical Neuroscience</i> , 2021, 23, 1-2.	1.8	3
47	Neurocognitive functioning in bipolar disorder: What we know and what we don't. <i>Dialogues in Clinical Neuroscience</i> , 2021, 23, 29-38.	1.8	20
48	Emotional memory in bipolar disorder: Impact of multiple episodes and childhood trauma. <i>Journal of Affective Disorders</i> , 2020, 260, 206-213.	2.0	6
49	Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis. <i>Bipolar Disorders</i> , 2020, 22, 360-371.	1.1	16
50	Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 298-307.	1.3	8
51	Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 290-300.	0.9	33
52	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 230-256.	1.0	38
53	The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary. <i>Bipolar Disorders</i> , 2020, 22, 788-804.	1.1	61
54	The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary. <i>Bipolar Disorders</i> , 2020, 22, 805-821.	1.1	87

#	ARTICLE	IF	CITATIONS
55	Mental Health of Communities during the COVID-19 Pandemic. Canadian Journal of Psychiatry, 2020, 65, 681-687.	0.9	157
56	Remission and recurrence in bipolar disorder: The data from health outcomes and patient evaluations in bipolar disorder (HOPE-BD) study. Journal of Affective Disorders, 2020, 268, 150-157.	2.0	15
57	Treatment of Mixed Features in Bipolar Disorder: an Updated View. Current Psychiatry Reports, 2020, 22, 15.	2.1	4
58	156 The Broad Efficacy of Cariprazine Across Symptoms in Patients with Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials. CNS Spectrums, 2020, 25, 300-300.	0.7	0
59	145 Incidence and Characteristics of Akathisia and Restlessness During Cariprazine Treatment for Bipolar I Disorder. CNS Spectrums, 2020, 25, 292-292.	0.7	0
60	The case for improved care and provision of treatment for people with first-episode mania. Lancet Psychiatry, the, 2019, 6, 869-876.	3.7	46
61	Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy, 2019, 20, 2063-2072.	0.9	12
62	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. Bipolar Disorders, 2019, 21, 582-594.	1.1	74
63	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.1	71
64	Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force. Bipolar Disorders, 2019, 21, 686-719.	1.1	69
65	The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC â€•BD). Bipolar Disorders, 2019, 21, 6-10.	1.1	12
66	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity â€• a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	1.3	20
67	Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. American Journal of Psychiatry, 2019, 176, 439-448.	4.0	85
68	Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review. CNS Drugs, 2019, 33, 431-456.	2.7	29
69	Childbirth and prevention of bipolar disorder: an opportunity for change. Lancet Psychiatry, the, 2019, 6, 786-792.	3.7	14
70	Objective and biological markers in bipolar spectrum presentations. Expert Review of Neurotherapeutics, 2019, 19, 195-209.	1.4	2
71	Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine. Psychiatry Research, 2019, 272, 144-148.	1.7	4
72	Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective <sc>MRI</sc> study. Bipolar Disorders, 2019, 21, 50-60.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. <i>Journal of Affective Disorders</i> , 2019, 245, 679-685.	2.0	31
74	Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. <i>Journal of Affective Disorders</i> , 2019, 246, 861-866.	2.0	8
75	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	1.7	54
76	Biomarkers in mood disorders: Are we there yet?. <i>Journal of Affective Disorders</i> , 2018, 233, 1-2.	2.0	16
77	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 108-113.	1.0	10
78	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
79	Structural brain changes in first episode mania with and without psychosis: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>World Journal of Biological Psychiatry</i> , 2018, 19, S30-S40.	1.3	10
80	Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis. <i>Journal of Affective Disorders</i> , 2018, 227, 109-116.	2.0	20
81	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	1.3	32
82	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 2-58.	1.3	128
83	The impact of psychosis on brain anatomy in bipolar disorder: A structural MRI study. <i>Journal of Affective Disorders</i> , 2018, 233, 100-109.	2.0	35
84	Course and naturalistic treatment seeking among persons with first episode mania in India: A retrospective chart review with up to five years follow-up. <i>Journal of Affective Disorders</i> , 2018, 240, 183-186.	2.0	5
85	Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	4
86	The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines.. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw109.	1.0	151
87	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw072.	1.0	44
88	Hippocampal neurochemical markers in bipolar disorder patients following the first-manic episode: A prospective 12-month proton magnetic resonance spectroscopy study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 65-74.	1.3	9
89	Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 210, 403-407.	1.7	50
90	Staging in bipolar disorder: from theoretical framework to clinical utility. <i>World Psychiatry</i> , 2017, 16, 236-244.	4.8	160

#	ARTICLE	IF	CITATIONS
91	Subcortical structural volumes in recently remitted first episode mania. <i>Journal of Affective Disorders</i> , 2017, 222, 23-27.	2.0	9
92	Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 16.	0.8	8
93	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2017, 208, 291-297.	2.0	20
94	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 441-448.	1.1	18
95	Metacognitive knowledge and experience in recently diagnosed patients with bipolar disorder. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 730-744.	0.8	17
96	The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2016, 30, 405-417.	2.7	11
97	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 576-587.	0.9	227
98	Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. <i>World Psychiatry</i> , 2016, 15, 85-86.	4.8	60
99	Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>Lancet Psychiatry</i> , 2016, 3, 1138-1146.	3.7	109
100	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw100.	1.0	77
101	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw091.	1.0	28
102	Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first episode mania and association with clinical outcome. <i>Bipolar Disorders</i> , 2016, 18, 511-519.	1.1	64
103	The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2016, 203, 55-61.	2.0	23
104	An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 271-281.	4.0	154
105	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016, 208, 146-152.	1.7	16
106	Assessment and management of agitation in psychiatry: Expert consensus. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 86-128.	1.3	204
107	Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial. <i>British Journal of Psychiatry</i> , 2016, 208, 78-86.	1.7	64
108	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2016, 73, 56.	6.0	191

#	ARTICLE	IF	CITATIONS
109	Response inhibition and interference control in patients with bipolar I disorder and first-degree relatives. <i>Bipolar Disorders</i> , 2015, 17, 781-794.	1.1	24
110	Course and outcome following a first episode of mania: Four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM). <i>Journal of Affective Disorders</i> , 2015, 175, 411-417.	2.0	18
111	Are cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study. <i>European Neuropsychopharmacology</i> , 2015, 25, 223-230.	0.3	21
112	A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1006-1020.	1.3	87
113	Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 785-802.	1.3	122
114	Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. <i>Journal of Affective Disorders</i> , 2015, 185, 90-96.	2.0	24
115	The relationship between burnout and depressive symptoms in patients with depressive disorders. <i>Journal of Affective Disorders</i> , 2015, 172, 361-366.	2.0	32
116	Cognitive performance and quality of life early in the course of bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 168, 119-124.	2.0	34
117	Impact of depressive episodes on cognitive deficits in early bipolar disorder: data from the Systematic Treatment Optimization Programme for Early Mania (STOP-EM). <i>British Journal of Psychiatry</i> , 2014, 205, 36-43.	1.7	11
118	Sex differences in cognitive functioning in patients with bipolar disorder who recently recovered from a first episode of mania: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2014, 155, 162-168.	2.0	28
119	Body Mass Index-Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients. <i>Biological Psychiatry</i> , 2014, 76, 138-145.	0.7	48
120	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. <i>Bipolar Disorders</i> , 2013, 15, 1-44.	1.1	740
121	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. <i>Bipolar Disorders</i> , 2013, 15, 58-60.	1.1	14
122	Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. <i>Journal of Affective Disorders</i> , 2013, 147, 365-372.	2.0	40
123	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. <i>Bipolar Disorders</i> , 2012, 14, 478-487.	1.1	184
124	The International Society for Bipolar Disorders' Battery for Assessment of Neurocognition (ISBD-BANC). <i>Bipolar Disorders</i> , 2010, 12, 351-363.	1.1	218
125	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2010, 12, 616-626.	1.1	31
126	The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. <i>Acta Neuropsychiatrica</i> , 2009, 21, 272-274.	1.0	29

#	ARTICLE	IF	CITATIONS
127	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. <i>Bipolar Disorders</i> , 2009, 11, 225-255.	1.1	545
128	CANMAT guidelines: authors'™ response. <i>Bipolar Disorders</i> , 2009, 11, 773-773.	1.1	0
129	CANMAT/ISBD treatment guidelines: response to Shen et al.. <i>Bipolar Disorders</i> , 2009, 11, 775-775.	1.1	0
130	Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 105-112.	0.9	85
131	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. <i>International Clinical Psychopharmacology</i> , 2007, 22, 212-220.	0.9	64
132	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. <i>Bipolar Disorders</i> , 2006, 8, 721-739.	1.1	202
133	Translating knowledge of genetics and pharmacology into improving everyday practice. <i>Bipolar Disorders</i> , 2005, 7, 13-20.	1.1	8
134	Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. <i>Bipolar Disorders</i> , 2005, 7, 5-69.	1.1	321
135	Quetiapine Versus Placebo in Combination With Lithium or Divalproex for the Treatment of Bipolar Mania. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 599-606.	0.7	147
136	Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. <i>Bipolar Disorders</i> , 2003, 5, 85-97.	1.1	46
137	Risperidone in acute and continuation treatment of mania. <i>International Clinical Psychopharmacology</i> , 2003, 18, 227-235.	0.9	36
138	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. <i>American Journal of Psychiatry</i> , 2002, 159, 768-774.	4.0	123
139	Third Generation Anticonvulsants in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 275-283.	1.1	65
140	Mood stabilization and the role of antipsychotics. <i>International Clinical Psychopharmacology</i> , 2002, 17 Suppl 3, S21-7.	0.9	2
141	Effects of Alpha-Methyl-Para-Tyrosine-Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission. <i>Neuropsychopharmacology</i> , 2001, 25, S97-S101.	2.8	35
142	Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. <i>Bipolar Disorders</i> , 2000, 2, 77-92.	1.1	78
143	Growth hormone response to baclofen in patients with mania: a pilot study. <i>Psychopharmacology</i> , 1999, 147, 280-284.	1.5	19
144	Clinical Predictors of Short-Term Outcome in Electroconvulsive Therapy. <i>Canadian Journal of Psychiatry</i> , 1999, 44, 158-163.	0.9	16

#	ARTICLE	IF	CITATIONS
145	Paraphrenia Redefined. Canadian Journal of Psychiatry, 1999, 44, 133-137.	0.9	12
146	Divalproex Sodium Attenuates Growth Hormone Response to Baclofen in Healthy Human Males. Neuropsychopharmacology, 1998, 18, 370-376.	2.8	9
147	L-Tryptophan Augmentation of Light Therapy in Patients with Seasonal Affective Disorder. Canadian Journal of Psychiatry, 1997, 42, 303-306.	0.9	35
148	Effects of Divalproex Sodium on 5-HT1A Receptor Function in Healthy Human Males: Hypothermic, Hormonal, and Behavioral Responses to Ipsapirone. Neuropsychopharmacology, 1997, 17, 382-390.	2.8	20
149	Treatment of Acute Bipolar Depression: A Review of the Literature. Canadian Journal of Psychiatry, 1995, 40, 533-544.	0.9	42